Biocon informs about disclosure

14 Mar 2024 Evaluate
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) read with Para A of Part A of Schedule III of the SEBI Listing Regulations, Biocon has informed that Biocon Biologics, a subsidiary of Biocon has approved the transfer of businesses in relation to its branded formulationsin India, comprising of Metabolics, Oncology And Critical Care Diagnostic (BFI Business) to Eris Lifesciences on a ‘slump sale’ basis. In this regard, it has enclosed the Press Release titled ‘Biocon Biologics Enters a Long-term Commercial Collaboration with Eris Lifesciences to Expand Patient Access in India’. Further, the details as required under Regulation 30 of SEBI Listing Regulations read with SEBI circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, are enclosed as ‘Annexure - I’.

The above information is a part of company’s filings submitted to BSE.

Biocon Share Price

366.55 -9.45 (-2.51%)
20-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1612.00
Dr. Reddys Lab 1166.90
Cipla 1377.85
Zydus Lifesciences 872.95
Lupin 2166.10
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×